Athanasios Michos (Greece)
National and Kapodistrian University of Athens, Greece First Pediatric DepartmentAuthor Of 9 Presentations
Q&A
Expert
Panel discussion
Moving forward – male HPV vaccination programs in Europe
Welcome and introduction
Reflection points and close
CHARACTERISTICS OF CHILDREN HOSPITALIZED WITH MIS-C DURING THREE PANDEMIC WAVES IN GREECE
Abstract
Backgrounds:
The Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but potentially severe complication of COVID-19.
Methods
This is a retrospective observational study of children aged <18 years hospitalized with MIS-C in 10 tertiary hospitals in Greece during three pandemic waves characterized by different SARS-CoV-2 variant: i. from August 2020 to January 2021 (EU1-B.1.177), ii. from February 2021 to July 2021 (Alpha-B.1.1.7) and iii. from August 2021 to December 2021 (Delta-B.1.617.2). The aim of the study was to document the incidence over time, clinical characteristics and outcome of children admitted with MIS-C in Greek hospitals during the COVID-19 pandemic.
Results:
In total, 119 patients were included, 91.6% (109/119) met the WHO criteria of MIS-C diagnosis: 26.9% (32/119), 39.5% (47/119) and 33.6% (40/119) were hospitalized during the 1st, 2nd, and 3rd study period, respectively. Demographic and clinical characteristics are shown in Table 1. No cases were found before October 2020. The incidence of MIS-C significantly decreased over the three waves from 3.3/1000 to 0.25/1000 confirmed COVID-19 cases (P <0.0001). No other significant difference was observed in the clinical manifestations and disease severity of children hospitalized with MIS-C over the three waves.
Conclusions/Learning Points:
This study indicates that the incidence of MIS-C may vary according to the predominant variant. Outcome remains favourable regardless of the variant leading to MIS-C. Larger studies are needed to clarify if clinical characteristics and/or disease severity may differ, as well.
IMMUNOGENICITY OF THE BNT162B2 COVID-19 VACCINE IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH CYSTIC FIBROSIS
Abstract
Backgrounds:
Cystic fibrosis (CF) patients constitute a high-risk group for severe COVID-19. We prospectively measured total (TAbs-RBD; U/ml) and neutralizing (NAbs-RBD; %) antibodies of SARS-CoV-2 spike-RBD protein before immunization, 20 days after the 1st and 30 days after the 2nd dose of the BNT162b2 vaccine in CF patients and healthy controls.
Methods
Serum samples were tested using the Elecsys® Anti-SARS-CoV-2 S reagent. Values of ≥0.8 U/ml are positive. The determination of anti-RBD neutralization titers was carried out using the Food and Drug Administration(FDA) approved blocking ELISA cPassTM SARS-CoV-2 neutralization antibody detection kit. Percentages of ≥ 30% were positive. A statistical analysis was performed for the comparison of the two groups and the possible association of antibody levels with epidemiological and clinical parameters.
Results:
A total of 33 patients with CF and 66 healthy controls were included in the study. The median age (IQR) of the CF group was 19.6 (17.6-24.3) years and 18 (54.5%) were females. CF patients had statistically significant higher antibody responses regarding TAbs-RBD and NAbs-RBD after both doses (P-value<0.001). One month after the 2nd dose, CF and controls had TAbs-RBD (IQR): 3396 (2443) and 1452 (1231) U/ml, respectively. Similarly, the NAbs-RBD (%) were: 97.30 (1.00) and 95.70 (3.71) (%), respectively. Among CF patients no statistically significant differences were detected for TAbs-RBD or NAbs-RBD regarding gender, pancreatic status, CFTR genotype of CF, use of CFTR modulators and chronic Pseudomonas Aeruginosa infection.
Conclusions/Learning Points:
The BNT162b2 vaccine was more immunogenic in patients with CF patients compared to healthy controls regardless of the CFTR genotype, related comorbidities, treatment type or severity of disease. Longitudinal studies regarding the kinetics of antibodies will be important to determine the appropriate timing for a booster dose in this population.
TOTAL AND NEUTRALIZING SARS-COV-2 SPIKE ANTIBODIES ONE, FOUR AND EIGHT MONTHS AFTER BNT162B2 IMMUNIZATION IN HEALTHCARE WORKERS FROM A MAJOR TERTIARY PEDIATRIC HOSPITAL
Abstract
Backgrounds:
Long-term data regarding the association of antibody levels after immunization with the BNT162b2 mRNA COVID-19 vaccine with epidemiological and clinical parameters are limited. We prospectively measured the total(TAbs) and neutralizing antibodies(NAbs) against the receptor binding domain(RBD) of SARS-CoV-2 spike protein in healthcare workers(HCWs) 1, 4 and 8 months after the 2nd dose of the BNT162b2 vaccine.
Methods
Serum samples from 462 HCWs of ‘‘Aghia Sophia’’ Children’s Hospital, Greece were collected and tested for TAbs-RBD using the Elecsys® Anti-SARS-CoV-2 S reagent and for NAbs-RBD using the Food and Drug Administration (FDA) approved blocking ELISA cPassTM SARS-CoV-2 neutralization antibody detection kit. A statistical analysis for possible association of antibodies’ levels with epidemiological and clinical parameters was performed.
Results:
The mean age (±SD) of the participants was 48.33 years (± 12.98) and 361(77.1%) were females. No significant differences in TAbs-RBD and NAbs-RBD were detected regarding gender and history of autoimmune diseases. A statistically significant negative association of NAbs-RBD was detected for age (β=-0.046, P<0.001). Smokers had significantly lower TAbs-RBD and NAbs-RBD (P<0.05) than non-smokers in each time-point of the study. TAbs-RBD in HCWs with underlying diseases significantly declined in all time points (P=0.005). HCWs with allergies showed higher TAbs-RBD in 1 and 4 months after the 2nd dose (P=0.003 and P=0.008 respectively). HCWs with AB blood type had lower TAbs-RBD than the other blood types in all time-points (P=0.044), especially 4 months after the 2nd dose (P=0.014).
Conclusions/Learning Points:
A significant gradual decline in TAbs and NAbs was detected within the first 8 months after the 2nd dose. Our findings support that older age and smoking negatively affect antibody levels, thus the administration of a booster dose in those groups is highly recommended.
Presenter of 6 Presentations
Moving forward – male HPV vaccination programs in Europe
Welcome and introduction
Reflection points and close
Q&A
Expert
Panel discussion
Moderator of 3 Sessions
Session Description:
This symposium aims to highlight recent therapeutic advances in the management of bacterial infections in paediatric patients. Throughout this pragmatic session, through patient case studies, our expert faculty will highlight the urgent need for safe and effective treatment options to address the current and anticipated burden of bacterial disease. While one speaker will address the growing threat of multidrug-resistant (MDR) Gram-negative infections and explore how alternative treatment options could improve patient outcomes, another expert will challenge the current standard of care used to treat community-acquired pneumonia (CAP) and complicated skin and soft tissue infections (cSSTIs), reviewing the potential role of therapeutic advances in meeting a clinical unmet need. The symposium will close with a panel discussion, where our esteemed faculty will discuss topics including the need for right-first-time treatment decisions, risk factors for infection in paediatric patients and the role of the multidisciplinary team in effective patient management. Additionally, there will be an opportunity for the audience to engage with the faculty by submitting pressing questions during the discussion for the panel to address.
Facilitator Of
Session Description:
This symposium aims to highlight recent therapeutic advances in the management of bacterial infections in paediatric patients. Throughout this pragmatic session, through patient case studies, our expert faculty will highlight the urgent need for safe and effective treatment options to address the current and anticipated burden of bacterial disease. While one speaker will address the growing threat of multidrug-resistant (MDR) Gram-negative infections and explore how alternative treatment options could improve patient outcomes, another expert will challenge the current standard of care used to treat community-acquired pneumonia (CAP) and complicated skin and soft tissue infections (cSSTIs), reviewing the potential role of therapeutic advances in meeting a clinical unmet need. The symposium will close with a panel discussion, where our esteemed faculty will discuss topics including the need for right-first-time treatment decisions, risk factors for infection in paediatric patients and the role of the multidisciplinary team in effective patient management. Additionally, there will be an opportunity for the audience to engage with the faculty by submitting pressing questions during the discussion for the panel to address.
Poster Author Of 12 e-Posters
EP051 - ROTAVIRUS SURVEILLANCE DURING COVID-19 PANDEMIC (ID 1470)
EP121 - A 12YEAR EPIDEMIOLOGICAL STUDY OF VISCERAL LEISHMANIASIS AT A TERTIARY PEDIATRIC HOSPITAL (ID 950)
EP416 - ACUTE APPENDICITIS ASSOCIATED WITH SARS-COV-2 INFECTION: COINCIDENCE OR COMPLICATION? (ID 1921)
EP467 - RAPID ANTIGEN TEST FOR DIAGNOSIS OF SARS-COV2 INFECTION IN THE PAEDIATRIC EMERGENCY DEPARTMENT OF A TERTIARY HOSPITAL (ID 1312)
EP490 - COMPARISON OF ACUTE PNEUMONIA CAUSED BY SARS-COV-2 AND INFLUENZA A IN CHILDREN: A RETROSPECTIVE COHORT STUDY (ID 1439)
EP529 - REMDESIVIR ADMINISTRATION IN CHILDREN WITH SARS-COV-2 INFECTION: A 2-YEAR EXPERIENCE (ID 1885)
PD118 - MOLECULAR EPIDEMIOLOGY OF UNUSUAL G OR P ROTAVIRUS A GENOTYPES IN CHILDREN WITH GASTRENTERITIS (ID 1326)
PD128 - ROTAVIRUS EPIDEMIOLOGY AND GENOTYPE DISTRIBUTION: A 12-YEAR GREEK NATIONAL MULTICENTER STUDY (ID 1400)
PD155 - SEROEPIDEMIOLOGY OF SARS-COV-2 IN PEDIATRIC POPULATION DURING A 16-MONTH PERIOD PRIOR TO VACCINATION (ID 1170)
PD161 - SEROPREVALENCE OF SARS-COV-2 INFECTION AMONG CHILDREN AND THEIR PARENTS IN GREECE (ID 786)
- Dimitra Dimopoulou (Greece)
- Maria Kyritsi (Greece)
- Eleni Vergadi (Greece)
- Ekaterini Tsiligianni (Greece)
- Eleni Papadimitriou (Greece)
- Artemis Mavridi (Greece)
- Spyridon Giannakopoulos (Greece)
- Georgia Tsiourvopoulou (Greece)
- Maria Palyvou (Greece)
- Evangelia Angeli (Greece)
- Nikitas Brikos (Greece)
- IRINI ELEFTHERIOU (Greece)
- Nikos SPYRIDIS (Greece)
- Athanasios Michos (Greece)
- Vassiliki Spoulou (Greece)
- Despoina Gkentzi (Greece)
- Ekaterini Siomou (Greece)
- Vassiliki Papaevangelou (Greece)
- George A. Syrogiannopoulos (Greece)
- Emmanouil Galanakis (Greece)
- Christos Hadjichristodoulou (Greece)
- Maria Tsolia (Greece)
PD168 - MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C): A NATIONWIDE COLLABORATIVE STUDY IN THE GREEK POPULATION (ID 774)
- STAVROULA LAMPIDI (Greece)
- Despoina Maritsi (Greece)
- IRINI ELEFTHERIOU (Greece)
- Evaggelia Farmaki (Greece)
- Nikos SPYRIDIS (Greece)
- KONSTANTINA CHARISI (Greece)
- Petrina Vantsi (Greece)
- Filippos G. Filippatos (Greece)
- Kleopatra Skourti (Greece)
- EFIMIA PAPADOPOULOU-ALATAKI (Greece)
- Kyriaki Papadopoulou-Legbelou (Greece)
- Parthena Kampouridou (Greece)
- Ioanna N. Grivea (Greece)
- Eleni Vergadi (Greece)
- Despoina Gkentzi (Greece)
- Despina Dimou (Greece)
- Patra Koletsi (Greece)
- Lampros Fotis (Greece)
- Vassiliki Papaevangelou (Greece)
- Gabriel Dimitriou (Greece)
- Emmanouil Galanakis (Greece)
- George A. Syrogiannopoulos (Greece)
- Vassiliki Spoulou (Greece)
- Athanasios Michos (Greece)
- Emmanuel Roilides (Greece)
- Maria Tsolia (Greece)
PD180 - SEROTYPE DISTRIBUTION OF STREPTOCOCCUS PNEUMONIAE CAUSING INVASIVE AND NON- INVASIVE DISEASE IN CHILDREN ≤ 14 YEARS OF AGE IN GREECE ΙΝ THE LAST 5 YEARS (2015-2020) (ID 1236)
- Emmanouil I. Koutouzis (Greece)
- George L. Daikos (Greece)
- Charilaos Dellis (Greece)
- Athanasios Michos (Greece)
- Anthi Sideri (Greece)
- George Kalogeras (Greece)
- Theano Georgakopoulou (Greece)
- Elizabeth- Barbara Tatsi (Greece)
- Foteini I. Koutouzi (Greece)
- Theodota Liakopoulou (Greece)
- Levantia Zachariadou (Greece)
- Vassiliki Syriopoulou (Greece)